Form 4 for MRK Merck & Co.
Accepted 2025-01-29 00:00:00 ET · period of report 2025-01-27 · accession 0001127602-25-002341 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-29 | 2025-01-27 | MRK | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | A - Grant | $97.94 | +25.4K | 179.0K | +17% | +$2.49M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-27 | A | A | 25,438 | $97.94 | 178,992.71 | D | — | — | (F1) Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024. (F2) Holdings include shares acquired in dividend reinvestment transactions. |